gi-hepatology
REACH-B Score for HCC Risk in Chronic Hepatitis B
Risk Estimation for Hepatocellular Carcinoma in Chronic Hepatitis B (REACH-B). Predicts 3-year, 5-year, and 10-year HCC risk in non-cirrhotic HBeAg-negative patients with chronic HBV. Based on sex, age, ALT, HBeAg status, and HBV DNA. Score 0-17. Developed by Yang et al. 2011 from the REVEAL-HBV cohort (n=3,584). NOT validated in cirrhotic patients.
References
- Yang HI et al. Development of a simple nomogram for the prediction of hepatocellular carcinoma in chronic hepatitis B patients with genotype C. J Hepatol. 2008;49(6):936-944.
- NICE NG133. Hepatitis B (chronic): diagnosis and management. NICE. 2013 (updated 2021).
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Drugs
- Omalizumab (Dermatology — Chronic Urticaria) · Anti-IgE Monoclonal Antibody
- Cetuximab · Anti-EGFR Monoclonal Antibody — Head and Neck Cancer
- Cisplatin · Platinum Chemotherapy — Head and Neck Cancer
- Fentanyl Transdermal Patch (Elderly Chronic Pain) · Opioid Analgesic — Transdermal Patch
- Morphine Slow-Release (Elderly Chronic Pain) · Opioid Analgesic — Modified-Release Oral
- Entecavir · Antiviral — Hepatitis B (Nucleoside Analogue)
Decision support only — verify against MDCalc, NICE, or your local guideline before clinical use.